Faruqi and Faruqui, LLP Logo
Share this page

Endologix, Inc. (ELGX)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Endologix, Inc. To Contact The Firm Before Lead Plaintiff Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Endologix, Inc. (“Endologix” or the “Company”) (NASDAQ:ELGX) of the March 6, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased Endologix securities between August 2, 2016 and November 16, 2016 (the “Class Period”).  The case, Vicky Nguyen v. Endologix, Inc. et al, No. 2:17-cv-00017 was filed on January 3, 2017, and has been assigned to Judge Andre Birotte Jr.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Endologix did not have the requisite clinical data for U.S. Food and Drug Administration (“FDA”) premarket approval of the Nellix® EndoVascular Aneurysm Sealing System (“Nellix EVAS System”); and (2) as a result, Endologix’s public statements were materially false and misleading.

Specifically, pre-market on November 16, 2016, Endologix issued a press release entitled “Endologix Provides Update on Nellix PMA Process,” revealing “that the FDA requested the Company provide 2-year patient follow-up data from the EVAS-FORWARD IDE Study of the Nellix EVAS System.”

After the announcement, Endologix’s share price fell from $9.84 per share on November 15, 2016 to a closing price of $7.82 on November 16, 2016—a $2.02 or a 20.53% drop.

Take Action

If you invested in Endologix stock or options between August 2, 2016 and November 16, 2016 and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Endologix’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Endologix, Inc. (ELGX)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 01/05/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.